Vir Biotechnology
Filed with the SEC on · accession 0001628280-26-071908
VIR filed a 8-K (current report) with the SEC on Nov 9, 2026. Vir Biotechnology announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in chronic hepatitis delta, meeting primary and key secondary endpoints with a 44% and 79% response rate, respectively, and a favorable safety profile.
Vir Biotechnology announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in chronic hepatitis delta, meeting primary and key secondary endpoints with a 44% and 79% response rate, respectively, and a favorable safety profile. Expanded Week 96 data from the Phase 2 SOLSTICE study also showed 100% of patients achieving undetectable viremia and encouraging liver health improvements.
✦ Ask GOAX AI about this filing — what it means for VIR, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for VIR?
Click hereVIR filed a 8-K (Fda approval). Vir Biotechnology announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in chronic hepatitis delta, meeting primary and key secondary endpoints with a 44% and 79% response rate, respectively, and a favorable safety profile. Expanded Week 96 data from the Phase 2 SOLSTICE study also showed 100% of patients achieving undetectable viremia and encouraging liver health improvements.
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Get alerts when VIR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days